The Breast Cancer Action Team
What does it mean to be the breast cancer industry watchdog in 2021?
This year, when it became clear the Food and Drug Administration Acting Commissioner Janet Woodcock was a potential nominee for the permanent role of the head of the FDA, our team sprang into action. Because we understand how the inner workings of this agency affect the daily lives of people living with breast cancer, we insist that the FDA Commissioner MUST prioritize public health over industry interest and be committed to ensuring a balance between approval speed and drug safety and efficacy. We mobilized our community of activists to urge the Biden administration make a better choice
The Biden administration didn’t move forward with her nomination, thanks to fearless advocates like our members, who aren’t afraid to demand accountability from those involved in the politics of breast cancer.
Make a year-end donation today to ensure our watchdog work continues to be just as powerful in 2022.
We are unabashed in our demands. In 2021 we also mobilized around these rapid response issues:
This watchdog role is indispensable to the breast cancer industry, and we won’t stop in 2022.